Antibody-Drug Conjugates Attract Hefty Funding To ADC Therapeutics

 
• By John Davis
  
Chris Martin of ADC Therapeutics
Chris Martin, CEO of ADC Therapeutics • Source: ADC Therapeutics

More from Financing

More from Business